The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, at least nine polyQ disorders have been described, see bellow for a list. Among them Huntington’s disease (HD) is the most widespread.
Currently, the standard of care of such disorders is focused on symptomatic treatments as no effective therapeutic interventions aimed at the treatment or prevention of polyQ diseases exist. This calls for an urgent need of innovative therapeutic strategies.
We have identified a number of novel therapeutic factors capable of reducing the toxicity of mutated proteins causing polyQ diseases. Their administration to both in vitro and in vivo model systems of HD via state-of-the-art gene therapy delivery systems resulted in amelioration of the detrimental effects of the mutant HTT gene, i.e., in reduced cell death, oxidative stress, transcriptional alterations, and alleviated motor deficit.

TRL 3/4 / 9

Inventors

Martello
Graziano

Ferlazzo
Giorgia
Maria

Gambetta
Anna
Maria

Leeb
Martin

Download the brochure

  • Method of treatment for human cytomegalovirus associated infections

    Human cytomegalovirus (HCMV) is a ubiquitous beta-herpesvirus that infects from 60% to nearly 80% of the human population worldwide and, although rarely, causes serious multi-organ infections, such as pneumonia, gastrointestinal diseases and retinitis, which can be fatal in immunosuppressed patients.[...]

  • SerpinB3 inhibitor for tumor treatment

    Expression of SerpinB3, a member of serine-protease inhibitor family, is associated with the carcinogenesis process as it determines resistance to apoptosis, induces cell proliferation and greater cell invasiveness. Furthermore, it leads to impaired immune surveillance and reduced chemosensitivity. Recent studies[...]

  • Use of small molecules to rescue folding defective proteins

    The use of CFTR (cystic fibrosis transmembrane conductance regulator) correctors for the treatment of rare and devastating genetic muscular diseases, namely sarcoglycanopathies and Brody myopathy, is the object of this invention. Sarcoglycanopathies and Brody myopathy are rare inherited striated muscle[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation